Moderna and Merck have reported positive initial results from the first late-stage trial of a personalized mRNA cancer vaccine for melanoma [1].
This development represents a potential shift in oncology, moving toward treatments tailored to the specific genetic makeup of an individual's tumor to prevent recurrence.
Stephane Bancel, CEO of Moderna, and Dr. Dean Li, President of Merck Research Laboratories, said the findings during an interview on CNBC’s ‘Squawk Box’ [1, 2]. The experimental treatment combines Moderna's personalized mRNA technology with Merck’s immunotherapy drug, Keytruda [1, 3].
The Phase 3 trial focused on patients with melanoma to determine if the combination therapy could extend disease-free survival more effectively than using Keytruda alone [1, 4]. The executives said the early data indicates an increased ability for patients to remain disease-free [2, 3].
Unlike traditional vaccines that prevent infection, this personalized vaccine is designed to treat existing cancer by teaching the immune system to recognize and attack specific mutations found in a patient's tumor [1, 4].
Market reaction to the trial data was immediate. Moderna’s stock price rose by approximately 50% following the announcement of the results [4].
The partnership between the two companies aims to validate whether the mRNA platform can be scaled for broader cancer applications beyond skin cancer [1, 3].
“Experimental personalized mRNA vaccine combined with Keytruda shows early promise.”
The transition of personalized mRNA vaccines into Phase 3 trials marks a critical step toward precision medicine in oncology. If these results are validated, it suggests that the technology used for COVID-19 vaccines can be adapted to treat complex diseases by targeting unique patient biomarkers, potentially reducing cancer recurrence rates for high-risk melanoma patients.
